{
    "eid": "2-s2.0-85063251559",
    "title": "Where latest advances in HIV are shared: 21st Bangkok International Symposium on HIV Medicine",
    "cover-date": "2019-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [],
    "authors": [
        "Pirapon June Ohata",
        "Win Min Han",
        "Donn Colby",
        "Stephen Kerr",
        "Anchalee Avihingsanon",
        "Thanyawee Puthanakit",
        "Nittaya Phanuphak",
        "Pich Seekaew",
        "Sasiwimol Ubolyam",
        "Sivaporn Gatechompol",
        "Eugene Kroon",
        "Kesdao Nanthapisal",
        "Chowalit Phadungphon",
        "Pornwinit Sattayamong",
        "Praphan Phanuphak"
    ],
    "citedby-count": 0,
    "ref-count": 18,
    "ref-list": [
        "A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration",
        "A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients",
        "Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): A randomised, open-label, non-inferiority trial",
        "Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis",
        "Timing of antiretroviral therapy for HIV-1 infection and tuberculosis",
        "Integration of antiretroviral therapy with tuberculosis treatment",
        "Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy",
        "Critical review: What dose of rifabutin is recommended with antiretroviral therapy?",
        "Efficacy of 400mg efavirenz versus standard 600mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial",
        "Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study",
        "Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV",
        "Prednisone for the prevention of paradoxical tuberculosis-associated IRIS",
        "HIV incidence among men who have sex with men after diagnosis with sexually transmitted infections",
        "Neuropsychological impairment in acute HIV and the effect of immediate antiretroviral therapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Pacific Biotech",
        "RND Diagnostics and Thailand Convention and Exhibition Bureau",
        "TCEB",
        "Gilead",
        "ViiV Healthcare"
    ]
}